Market Update Economic Events Directors Deals Commodities Prices News Market Movers

Oncimmune partner in Israel gets regulatory nod for product sales

Wednesday, 15th May 2019
Oncimmune Holdings said its distributor for Israel, Best Medical Opinion, had received regulatory approval for the sale of the company's lung-cancer screening product.

On an age standardised basis, Israel's lung cancer mortality rate was 18.2%, making it one of the highest rates in the Middle East region.

'We welcome this latest approval which paves the way for the near-term commencement of commercial sales in the sophisticated healthcare market of Israel,' chief executive Adam Hill said.

At 8:36am: (LON:ONC) Oncimmune Holdings Plc share price was 0p at 92.5p

Story provided by

Related Shares: Oncimmune

Share Search
Share Search Share Search

Visit the Share Search.
Share Search

Share News
Share News will do their best to ensure the quality of the information displayed on this site, but all information is provided as-is, free of charge. We cannot be held responsible for any loss, material or otherwise, due to incorrect information found here. UK data supplied by NBTrader and Digital Look. Share Prices are at least 15 minutes delayed.